News

This milestone was announced by Clearside Biomedical, Inc., Arctic Vision's partner. ARCATUS, also known as XIPERE®, utilizes a revolutionary suprachoroidal delivery platform, offering new hope to patients in China suffering from this vision-threatening condition.

The data was presented in a poster titled at the American Thyroid Association (ATA).

Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."

The collaboration will drive an effort to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vision loss for people with serious eye diseases.

Steven A. Greenstein, MD, emphasizes the importance of identifying and assessing eye emergencies, highlighting the need to determine when to escalate care from primary to subspecialty settings. He discusses various types of anterior segment emergencies, while stressing the significance of maintaining a calm demeanor in these critical situations.

An increase in sexually transmitted infections may be causing an increase in number of eye infections.

Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."

Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."

Educating patients about the importance of consistent care is key.

A rapid lateral-flow device shows high sensitivity and specificity in identifying Aspergillus species in corneal samples, aiding in diagnosing microbial keratitis. The device, coupled with ratiometric analysis, proves robust and cost-effective, potentially revolutionizing MK diagnosis, especially in low-resource settings

Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."

The MyopiaX-1 trial studies MyopiaX, a smartphone application that aims to slow the progression of myopia, or nearsightedness, in children and adolescents.

Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."

Investigators note a supply shortage led to use of half a dose for imaging purposes.

In this EyePod® episode, David Hutton sits down with Shankar Musunuri, CEO of Ocugen to discuss updated data for OCU400.

The organization is warning the public about the hazards of misusing contact lenses. Contact lens wearers also must take extra care when applying and removing eye cosmetics.

The effort will capture the real-life stories of patients and eye care professionals around the world.

According to the company, the divestment includes Xiidra, on-market treatment for dry eye disease and additional ophthalmic investigational therapies. Novartis will now move forward with a focused portfolio and prioritized therapeutic areas for future growth.

A team of University of Rochester scientists develop computer models of patients’ eyes to identify the ideal IOLs and visual simulators for patients to experience how they will see with them.

According to Outlook, in the FDA’s recently issued CRL it concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.

The specialty pharmaceutical research company’s new retinal vascular dysfunction model can have an impact on the research and development of new drugs for retinal vascular diseases.

In cases where patients struggle with applying or tolerating eye drops, especially after previous selective laser trabeculoplasty (SLT) treatment, MicroPulse transscleral laser therapy (TLT) offers a practical solution.

Kriya is developing a one-time gene therapy designed to block complement C3 and C5, which are clinically validated substrates targeted by FDA approved therapies, to delay the progression of geographic atrophy.

Efficacy of treatment option is also confirmed in pediatric population in India.

The Lasker-DeBakey Clinical Medical Research Award, dubbed ‘America’s Nobel,’ recognizes the wide use of optical coherence tomography to manage eye disease, prevent blindness.

The company announced its previously announced agreement to divest its late-stage ophthalmic assets to Laboratoires Théa S.A.S. has been terminated.

Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents.